While the current review focuses on depression, it is worth mentioning emerging evidence linking GLP-1 and GLP-1–based treatments to addiction, mediated by its effect on dopaminergic signaling (78, 79). The gene discussed is GLP1R; the disease is depressive symptom measurement.